高齢心不全患者のナトリウム・グルコース・コトランスポーター-2 阻害剤利用の予測:現実世界の人口レベルのデータセット分析
Zubair Bashir1, Ritika Saxena1, Wissam Khalife1
1Department of Cardiology, University of Texas Medical Branch, Galveston, Texas, USA.
The American journal of cardiology
|August 21, 2025
まとめ
心不全 (HF) の患者に対して,ナトリウム・グルコース・コトランスポーター-2 阻害剤 (SGLT2i) の使用における差異は持続しています. 年齢,人種,併発症などの要因は,SGLT2iの処方に影響し,HF治療への公平なアクセスが必要であることを強調しています.
科学分野:
- 心臓病科
- 薬理学について
- 医療サービス研究
背景:
- ナトリウム・グルコース・コトランスポーター2阻害剤 (SGLT2i) は,心不全の患者にとって重要な心血管上の利点をもたらします.
- HFのSGLT2i処方における現実世界の利用パターンと社会統計学的格差は,まだ十分に調査されていない.
研究 の 目的:
- HF患者におけるSGLT2iの予測要因を特定する.
- HF患者のSGLT2i利用における社会人口学的差異を調査する.
主な方法:
- テキサスのメディケアデータセットを使用した遡及コホート研究 (2017年1月 - 2022年6月).
- 分析には,SGLT2iの処方に関する独立した予測要因を決定するための記述的統計と多変数ロジスティック回帰が含まれていた.
- SGLT2iの使用の調整された限界確率は,人種/民族グループで推定された.
主要な成果:
- 309,577人のHF患者の中で,SGLT2i受容者は高齢者,女性,または非ヒスパニック系白人であった可能性が低い.
- 糖尿病,高血圧,肥満は,SGLT2iの処方率の増加と関連していました.
- CKD III/ IV 段階,外周血管疾患,尿路感染症は処方率の低下と関連していました.
- 調整されたSGLT2iの処方可能性はアジア人 (3. 96%) で最高で,黒人 (2. 26%) で最低でした.
結論:
- SGLT2iの処方には,年齢,人種/民族,および併発症の負担の影響で,大きな差異がある.
- ガイドラインに沿った医療療法への公平なアクセスは,HFの治療の格差を軽減するために不可欠です.
さらに関連する動画
12:59Improving Strength, Power, Muscle Aerobic Capacity, and Glucose Tolerance through Short-term Progressive Strength Training Among Elderly People
Published on: July 5, 2017
12.7K
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
214
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:22Heart Failure Drugs: Diuretics
483
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
483
01:22Heart Failure VI: Adjunct Therapies
27
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
27
01:27Glucose Transporters
24.1K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
24.1K
01:29Factors Affecting Protein-Drug Binding: Patient-Related Factors
114
Protein-drug binding, a pivotal aspect of pharmacokinetics, is subject to considerable variability influenced by an array of patient-related factors. The intricate interplay of age, individual differences, and pathological conditions significantly impact the binding dynamics and subsequent pharmacological effects.
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
Age stands as a key determinant in protein-drug binding. Neonates, characterized by low albumin content, experience heightened concentrations of unbound drugs such as phenytoin and...
114